Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.50 |
| ▸ | DRD2 | P14416 | 7/20 | 0.50 |
| ▸ | HTR2A | P28223 | 7/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259627 | 0.87 | MAOB (0.44) | HTR1ADRD2HTR2AADRA1DADRA1A | |
| SCHEMBL6403949 | 0.80 | HTR1A (0.60) | HTR1ADRD2HTR2AADRA1DADRA1A | |
| SCHEMBL8670836 | 0.78 | AHR (0.59) | HTR1ADRD2HTR2AADRA1DADRA1A | |
| SCHEMBL14560260 | 0.78 | HTR1A (0.64) | HTR1ADRD2HTR2AADRA1DADRA1A | |
| SCHEMBL261050 | 0.78 | MAOB (0.52) | MAOBKCNJ1KCNH2 | |
| SCHEMBL14560259 | 0.76 | HTR1A (0.63) | HTR1ADRD2HTR2AADRA1DADRA1A | |
| SCHEMBL3791486 | 0.75 | HTR1A (0.57) | HTR1ADRD2HTR2AADRA1DADRA1A | |
| SCHEMBL29673899 | 0.75 | HTR1A (0.45) | HTR1ADRD2HTR2AADRA1DADRA1A | |
| SCHEMBL29673925 | 0.73 | HTR1A (0.46) | HTR1ADRD2HTR2AADRA1DADRA1A | |
| SCHEMBL7349900 | 0.72 | AHR (0.53) | HTR1ADRD2HTR2AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653073-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-02-18 | — | — | US | disclosed |
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2013-12-12 | — | — | US | disclosed |
| US-8541412-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-09-24 | — | — | US | disclosed |
| EP-2281822-B1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2013-01-16 | — | — | EP | disclosed |
| US-8133889-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-13 | — | — | US | disclosed |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-02-23 | — | — | US | disclosed |
| WO-2011015728-A1 | NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2011-02-10 | — | — | WO | disclosed |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-02-10 | — | — | US | disclosed |
| EP-2281822-A1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP11B1, SDHA, CYP11B2 | HTR1A 935/4885DRD2 359/4885HTR2A 2651/4885 |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | HTR1A 935/4885DRD2 359/4885HTR2A 2651/4885 |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | HTR1A 935/4885DRD2 359/4885HTR2A 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.